Pentostatin Suppliers & Bulk Manufacturers
Available Forms: Injection
Available Strengths: 10 mg
Reference Brands: Nipent (USA/EU)
Category:
Oncology Cancer Care
Pentostatin is available in Injection
and strengths such as 10 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Pentostatin is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Pentostatin can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Pentostatin is a chemotherapeutic agent used primarily in the treatment of hematologic malignancies, most notably hairy cell leukemia. It is administered by intravenous infusion, typically once every two weeks over a treatment period of three to six months, depending on patient response and clinical protocol. Pentostatin works by inhibiting the enzyme adenosine deaminase, which leads to the accumulation of toxic metabolites in malignant lymphocytes and results in cancer cell death.
In addition to its approved use in hairy cell leukemia, pentostatin has been utilized in the treatment of other lymphoid disorders, including relapsed chronic lymphocytic leukemia (CLL) and T-cell prolymphocytic leukemia. It has also shown clinical benefit in patients with steroid-refractory acute and chronic graft-versus-host disease, particularly in cases where standard therapies have failed.
Pentostatin is marketed under the brand name Nipent and is supplied as a lyophilized powder for intravenous infusion. As a chemotherapy agent, its use requires careful patient monitoring due to potential adverse effects such as immunosuppression, infections, and hematologic toxicity. When administered under appropriate clinical supervision, pentostatin remains an effective and well-established option in the management of select leukemias and refractory immune-mediated conditions.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing